Control Biologic Rx Costs
Psoriasis & eczema drugs are an expensive and growing problem. Access millions in same-year returns deprescribing your highest-cost members with a >3:1 ROI guarantee.
Health Plans, PBMs, & Payers: target your highest-cost and highest-risk members to curb the biologic spend.

Biologic spend on psoriasis and eczema in 2025*
*IQVIA. (2026, April). Healthcare & pharmaceutical marketplace trends
Specialty drugs for psoriasis & eczema are 5 of the top 10 fastest growing drugs, growing by >$24B in 2025 and representing >$78B in total spend.
Decrease My SpendTrusted by both national and regional health plans across the country, access:
Utilization growth driving millions in unnecessary specialty dermatology drug spend
Specialty drugs meant for only the most severe cases are approved and now widely prescribed for moderate disease, too. Utilization growth is driven in part by consumer demand from heavy D2C advertising and traditional dermatologists who are quick to prescribe specialty drugs and know how to get them approved.
Many of our partners are surprised to learn just how much they’re spending on biologics for dermatology care – and how much of that spending may not be necessary.
Biologic spending has increased at a compound annual growth rate of 10% from 2014-2024. This is often aggregated in a small identifiable group of high-cost members.
See exactly how much you’ll save – based on your own claims data.
How many members do you provide health insurance for?
We estimate you are spending
on biologics for Eczema and Psoriasis.
With Zest, up to
can be avoided while improving access and patient outcomes.
Trusted by 20M+ members of national and regional health plans across the country, Zest Health is committed to improving outcomes and decreasing reliance on specialty drugs for psoriasis and eczema. Proactively right-size what is one of the fastest-growing categories of specialty drug spend by contacting us today.
By submitting the form, I agree to Zest's Terms and Policies.